SW120619 is a specific small molecule inhibitor of WNK3 kinase with IC50 of 0.7 uM, weakly inhibits WNK1 and WNK2 with IC50 of 2.3 and 16.8 uM, respectively.

U-510 is a three-tail Janus dendritic ionizable lipid containing an N-methyl tertiary amine, a hydroxypropyl head segment, an ester linker and three C8 ether-linked hydrophobic tails. In an intravenous luciferase-mRNA study in BALB/c mice, it showed a spleen-biased organ-expression profile within the U-509–U-512 series. The authors reported 52% spleen-targeting efficiency in the context of liver and spleen luminescence at 3 hours after 0.5 mg/kg mRNA; this is not a percentage of transfected spleen cells or injected dose. The U-510 LNP formulation had a reported size of 113 nm, PDI of 0.146, apparent LNP pKa of 6.38 and encapsulation efficiency of 87.88%. It supports preclinical evaluation of splenic mRNA expression rather than maximum whole-animal expression.

U-503 is a Janus dendritic ionizable lipid with two tertiary amines, two hydroxyl groups, two ester linkers and six C10 alkyl tails connected to dendritic cores through ether bonds. It was identified alongside the C8-tail analogue U-502 as a leading intravenous mRNA-expression candidate in a 16-lipid study. In BALB/c mice given 0.5 mg/kg luciferase mRNA, U-503 produced a modestly higher 3-hour expression signal than the ALC-0315 comparator under the reported formulation conditions. Its LNP formulation had a size of 114 nm, PDI of 0.122, apparent LNP pKa of 6.31 and encapsulation efficiency of 89.36%. U-503 is a preclinical research candidate for systemic mRNA delivery and matched tail-length comparisons with U-502.

U-502 is a Janus dendritic ionizable lipid with two tertiary amines, two hydroxyl groups and six C8 alkyl tails attached through ether-containing dendrons and ester linkers. In a 16-lipid study, U-502 and U-503 were the leading intravenous mRNA-expression candidates, with modestly higher luciferase signals than ALC-0315 in BALB/c mice at 0.5 mg/kg mRNA and a 3-hour readout. The U-502 formulation had a reported size of 108 nm, PDI of 0.125, apparent LNP pKa of 6.36 and mRNA encapsulation efficiency of 91.83%. U-502 also underwent cell transfection, lysosomal colocalization and representative tissue-histology studies. It supports preclinical research into liver-dominant systemic mRNA delivery and headgroup–tail structure–activity relationships.

iL-19 is an aminoethoxy-functionalized ionizable lipid with a triamine scaffold, two ester linkages and four doubly branched hydrophobic tails. It was identified as the overall lead for circular RNA delivery in a 2026 JACS study. With circRNA encoding firefly luciferase, iL-19 LNPs produced approximately 28-fold higher expression than the SM-102 benchmark in C2C12 cells and approximately 2.5-fold higher expression after intramuscular administration in BALB/c mice under the reported conditions. The reported circRNA formulation uses iL-19, DSPC, cholesterol and DMG-PEG2000 at 50:10:38.5:1.5 mol%. It supports preclinical investigation of circular RNA delivery to muscle; comprehensive safety and immunogenicity evaluation remains outstanding.

Dynein2-IN-37 (Ciliobrevin analog 37) is a potent, selective cytoplasmic dynein 2 ATPase activity antagonist with IC50 of 11 uM, shows weak inhibition for dynein 2 (IC50=280 uM).

DSPE-PEG2000-SC is a functionalized PEG lipid comprising a DSPE anchor, a PEG2000 spacer and a terminal succinimidyl carbonate group for conjugation with amine-containing molecules. It is suitable for bioconjugation and the development of ligand-functionalized lipid delivery systems. For research use only.

DSPE-PEG-SC consists of DSPE, PEG, and Succinimidyl Carbonate (SC) group. DSPE serves as lipid backbone, PEG improves solubility and reduces immunogenicity, SC as functional group enables efficient conjugation with amines. It enhances stability and targeted delivery efficiency. Please note that this product is intended for research purposes only.

SM-102 is an ionizable amino lipid that has been used in combination with other lipids in the formation of lipid nanoparticles.Administration of luciferase mRNA in SM-102-containing lipid nanoparticles induces hepatic luciferase expression in mice. Formulations containing SM-102 have been used in the development of lipid nanoparticles for delivery of mRNA-based vaccines.

IC8 is an ionizable cationic lipid. It has been used in combination with other lipids for the formation of lipid nanoparticles (LNPs). Immunization with severe acute respiratory coronavirus 2 (SARS-CoV-2) spike glycoprotein mRNA in IC8- and manganese-containing LNPs induces IgG responses to SARS-CoV-2 Delta and Omicron variants in mice.1 Administration of mRNA encoding B7-H3 X CD3 bispecific T cell engaging (BiTE) antibodies in IC8-containing LNPs reduces tumor growth in MV4-11 and A375 mouse xenograft models.

ALC 0366 is an ionizable cationic lipid (pKa = 6.25) from Biontech,which is derived from ALC-0315. ALC0366 has been used as a key component of LNP to deliver BNT142, a lipid nanoparticle (LNP)-formulated RNA (RNA-LNP) encoding a T cell-engaging bispecific antibody that monovalently binds the T cell marker CD3 and bivalently binds claudin 6 (CLDN6), an oncofetal antigen that is absent from normal adult tissue but expressed on various solid tumors.

iChol15-C4A2 is a groundbreaking ionizable cholesteryl lipid, expertly designed to overcome the primary challenge of liver-centric accumulation in mRNA therapeutics. Its innovative "two-in-one" structure seamlessly integrates cholesterol with an ionizable headgroup, enabling the formation of stable, three-component Lipid Nanoparticles (Tc-LNPs).The key advantage of Tc-LNPs formulated with iChol15-CA2 is their significantly reduced adsorption of Apolipoprotein E (ApoE).This unique property directly attenuates ApoE/LDLR-mediated uptake by liver cells, dramatically shifting biodistribution toward extrahepatic tissues. Peer-validated research demonstrates a remarkable 20-50 fold increase in the spleen-to-liver mRNA expression ratio compared to standard LNPs like ALC-0315, unlocking unparalleled potential for targeting the immune system. Beyond its superior targeting capability, iChol15-C4A2 ensures high mRNA encapsulation efficiency, excellent colloidal stability, and proven biocompatibility. It offers a powerful, off-the-shelf solution to advance next-generation mRNA applications, from innovative vaccines and cancer immunotherapies to treatments for splenic disorders. Discover how iChol15-C4A2 can transform your delivery platform.

Syn-TEF1 is a molecule actively enables transcription across repressive GAA repeats that silence frataxin expression in Friedreich's ataxia, license transcription elongation at targeted genomic loci.

Lipid 01-1 is an ionizable lipid investigated for lipid nanoparticle delivery of mRNA encoding a CD19/CD3 bispecific T-cell engager. In WO2024131874A1, 01-1-based LNPs supported serum antibody expression and were used in a Nalm6 leukemia model with human PBMCs. A single intravenous dose of mRNA1-LNPs reduced tumor bioluminescence relative to controls and the recombinant antibody regimen tested. Its structure combines a hydroxyl-bearing diamine headgroup, a cyclobutyl substituent and two ester-linked branched hydrophobic groups.

Lipid 03-135 is an ionizable lipid investigated for lipid nanoparticle delivery of mRNA encoding a CD19/CD3 bispecific T-cell engager developed by Abogen. In WO2024131874A1, its formulation showed the highest plotted serum antibody concentrations at 24 and 48 hours among five tested lipids after a single intravenous dose of mRNA1 in NOD/SCID mice.

MP2 is a methylprednisolone-derived ionizable lipid with a steroidal headgroup and three acetal-containing C8 tails. In the cited study, MP2 was formulated with DOPE, cholesterol and DMG-PEG2k for rectal mRNA delivery to inflamed colonic tissue. The MP2 formulation produced about 15-fold higher colonic luciferase signal than the study's SM102 formulation in TNBS colitis mice.

BP-200-C12 is a bisphosphonate-linked ionizable lipid selected from a 21-member library in Liu et al. for local RNA delivery at mineralized tissue interfaces.

Lipid 6 is the lead ionizable lipid among eight candidates screened by Gao et al. for mRNA delivery to primary human immune cells. Lipid 6 LNPs were used to generate MUC1-CAR T cells ex vivo and to assess their cytotoxicity against MUC1-positive cancer cell lines in vitro. Mouse reporter-mRNA expression was studied separately; in vivo antitumor efficacy of the CAR T cells was not established.

DBCO-PEG4-NHS Ester is a PEG derivative containing NHS ester that is able to react specifically and efficiently with primary amines (e.g. the side chain of lysine residues or aminosilane-coated surfaces) at neutral or slightly basic condition to form a covalent bond. The hydrophilic PEG spacer arm improves water solubility and provides a long and flexible connection that minimizes steric hindrance involved with ligation.

Kisspeptin-10 is a potent endogenous agonist for GPR54, used as a vasoconstrictor and an angiogenesis inhibitor.

OncoACP3 (Compound s43) is a high affinity ligand for prostatic acid phosphatase (ACP3). OncoACP3, radiolabelled with Lu-177, selectively accumulates in enzyme-expressing tumors and shows a potent anti-tumor activity with excellent tumor-selective payload deposition in HT1080.hACP3 and PC3.hACP3 tumor-bearing mice model. OncoACP3 can be used for prostate cancer research.

ACP3 ligand 1 (compound I11a) is a ligand against Acid Phosphatase 3 (ACP3, ACPP). ACP3 ligand 1 interacts with ACP3 expressed on the surface of tumor cells for in vivo pharmaco-delivery applications.

Piperaquine phosphate is a bisquinoline antimalarial agent. Piperaquine phosphate can be used in antimalarial research in combination with Artemisinin.

HFI-419 is an insulin-regulated aminopeptidase (IRAP) inhibitor. HFI-419 has inhibitory potency for IRAP with Ki value of 0.48 μM. HFI-419 can be used for the research of cognitive and memory impairments such as Alzheimer's disease, brain trauma, and stroke.

1,2-Dierucoyl->sn-glycero-3-PE is a phospholipid containing erucic acid (13(Z)-docosenoic acid;at the sn-1 and sn-2 positions. It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA in vivo.

AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345)-induced dermal fibrosis in mice.

NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays.

NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays.

H9 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. H9 LNPs shows superior mRNA transfection potency compared to LNPs containing (D-Lin-MC3-DMA).

A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine.